China Resources Pharmaceutical Group Dividende
Zukünftiges Wachstum Kriterienprüfungen 2/6
China Resources Pharmaceutical Group ist ein dividendenzahlendes Unternehmen mit einer aktuellen Rendite von 3.5%, die durch die Erträge gut gedeckt ist.
Wichtige Informationen
3.3%
Dividendenausschüttung
39%
Ausschüttungsquote
| Durchschnittlicher Branchenertrag | 3.5% |
| Nächster Dividendenzahlungstermin | n/a |
| Ex-Dividendendatum | n/a |
| Dividende pro Aktie | HK$0.184 |
| Gewinn pro Aktie | HK$0.60 |
| Prognose der Dividendenrendite | 3.7% |
Aktuelle Dividendenentwicklung
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01
China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14Recent updates
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17Stabilität und Wachstum des Zahlungsverkehrs
Rufe Dividendendaten ab
Stabile Dividende: Während die Dividendenzahlungen stabil waren, zahlt 3320 seit weniger als 10 Jahren eine Dividende.
Wachsende Dividende: 3320Die Dividendenzahlungen des Unternehmens sind gestiegen, aber das Unternehmen zahlt erst seit 7 Jahren eine Dividende.
Dividendenrendite im Vergleich zum Markt
| China Resources Pharmaceutical Group Dividendenrendite im Vergleich zum Markt |
|---|
| Segment | Dividendenrendite |
|---|---|
| Unternehmen (3320) | 3.3% |
| Untere 25 % des Marktes (HK) | 3.3% |
| Markt Top 25 % (HK) | 8.1% |
| Branchendurchschnitt (Pharmaceuticals) | 3.5% |
| Analystenprognose (3320) (bis zu 3 Jahre) | 3.7% |
Bemerkenswerte Dividende: 3320Die Dividende des Unternehmens (2.8%) ist im Vergleich zu den unteren 25 % der Dividendenzahler auf dem Markt Hong Kong (3.12%) nicht bemerkenswert.
Hohe Dividende: 3320Die Dividende des Unternehmens (3.06%) ist im Vergleich zu den besten 25% der Dividendenzahler auf dem Markt Hong Kong (8.28%) niedrig.
Gewinnausschüttung an die Aktionäre
Abdeckung der Erträge: Mit einer relativ niedrigen Ausschüttungsquote (25.1%) sind die Dividendenzahlungen von 3320 gut durch die Erträge gedeckt.
Barausschüttung an die Aktionäre
Cashflow-Deckung: Mit seiner niedrigen Cash Payout Ratio (7.7%) sind die Dividendenzahlungen von 3320 vollständig durch den Cashflow gedeckt.